ImmuPharma (LON:IMM) Shares Down 15.3% - Should You Sell?

Key Points

• ImmuPharma plc shares dropped by 15.3% to GBX 14.90 ($0.20), significantly up from a previous close of GBX 17.60 ($0.24) amid increased trading volume.
• The company reported a negative earnings per share of GBX (0.38) for the last quarter, with analysts predicting an EPS of -339 for the current year.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases and has a lead program aimed at treating Lupus with its drug Lupuzor™.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) fell 15.3% on Tuesday . The stock traded as low as GBX 14.50 ($0.20) and last traded at GBX 14.90 ($0.20). 30,500,184 shares traded hands during trading, an increase of 263% from the average session volume of 8,394,409 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Stock Down 15.3%

The firm's 50 day simple moving average is GBX 3.43 and its two-hundred day simple moving average is GBX 3.01. The stock has a market cap of £74.46 million, a P/E ratio of -1,674.16 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.